Skip to content

Study · Non-randomized trial · n = 16 · 1999

6 results

Cardiac effects of hexarelin in hypopituitary adults.

Bisi G, Podio V, Valetto MR, Broglio F, Bertuccio G, Aimaretti G, Pelosi E, Del Rio G, Muccioli G, Ong H, Boghen MF, Deghenghi R, Ghigo E

European journal of pharmacology1 Sept 1999Cited by 35 (Europe PMC)

PMID10528131 (opens in a new tab)DOI10.1016/s0014-2999(99)00537-3 (opens in a new tab)PepBankPUB-10528131
Publisher pagePubMedAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

  1. 01HumanNon-randomized trialActivity measurement

    In men with GH deficiency, the GH response to hexarelin was negligible compared with control men.

    In plain wordsIn men with growth hormone deficiency, hexarelin raised growth hormone far less than in healthy men.

    Peptide
    Hexarelin
    Outcome
    DecreaseGH response to hexarelin in GH deficiency versus controls
    Study

    n = 16

    Comparator
    Control subjects
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    Dose not stated · intravenousAs given in this study (human).

    Measurements

    Peak GH
    1.9 microg/l
    GH deficiency
    Peak GH
    45.7 microg/l
    controls

    Source sentences

    Summary
    The GH response to hexarelin was negligible in patients with GHD compared to control subjects (CS) (peak: 1.9+/-0.9 vs. 45.7+/-3.6 microg/l, P<0.001).
    1 context sentence
    Summary · context
    Seven adult male patients with GH deficiency (GHD) (age, mean+/-S.E.M.: 42.0+/-4.0 year) were studied by equilibrium radionuclide angiocardiography after i.v. administration of hexarelin, a peptide GH secretagogue.
  2. 02HumanNon-randomized trialSafety outcome

    In men with GH deficiency and controls, hexarelin did not change catecholamine levels.

    In plain wordsIn men with growth hormone deficiency and in healthy men, hexarelin did not change catecholamine levels.

    Peptide
    Hexarelin
    Outcome
    No significant changeCatecholamine levels
    Study

    n = 16

    Comparator
    Baseline
    Outcome group
    Hormone levels · Endocrine and hormones
    Studied dose
    Dose not stated · intravenousAs given in this study (human).

    Source sentences

    Summary
    Hexarelin administration increased LVEF both in patients with GHD and in CS (peak: 57+/-2 vs. 70+/-2, respectively, P<0.05 vs. baseline) without changing catecholamine levels, mean blood pressure (MBP), or cardiac output in either group.
    1 context sentence
    Summary · context
    Seven adult male patients with GH deficiency (GHD) (age, mean+/-S.E.M.: 42.0+/-4.0 year) were studied by equilibrium radionuclide angiocardiography after i.v. administration of hexarelin, a peptide GH secretagogue.
  3. 03HumanNon-randomized trialSafety outcome

    In men with GH deficiency and controls, hexarelin did not change mean blood pressure.

    In plain wordsIn men with growth hormone deficiency and in healthy men, hexarelin did not change mean blood pressure.

    Peptide
    Hexarelin
    Outcome
    No significant changeMean blood pressure
    Study

    n = 16

    Comparator
    Baseline
    Outcome group
    Blood pressure · Cardiovascular
    Studied dose
    Dose not stated · intravenousAs given in this study (human).

    Source sentences

    Summary
    Hexarelin administration increased LVEF both in patients with GHD and in CS (peak: 57+/-2 vs. 70+/-2, respectively, P<0.05 vs. baseline) without changing catecholamine levels, mean blood pressure (MBP), or cardiac output in either group.
    1 context sentence
    Summary · context
    Seven adult male patients with GH deficiency (GHD) (age, mean+/-S.E.M.: 42.0+/-4.0 year) were studied by equilibrium radionuclide angiocardiography after i.v. administration of hexarelin, a peptide GH secretagogue.
  4. 04HumanNon-randomized trialSafety outcome

    In men with GH deficiency and controls, hexarelin did not change cardiac output.

    In plain wordsIn men with growth hormone deficiency and in healthy men, hexarelin did not change cardiac output.

    Peptide
    Hexarelin
    Outcome
    No significant changeCardiac output
    Study

    n = 16

    Comparator
    Baseline
    Outcome group
    Heart function · Cardiovascular
    Studied dose
    Dose not stated · intravenousAs given in this study (human).

    Source sentences

    Summary
    Hexarelin administration increased LVEF both in patients with GHD and in CS (peak: 57+/-2 vs. 70+/-2, respectively, P<0.05 vs. baseline) without changing catecholamine levels, mean blood pressure (MBP), or cardiac output in either group.
    1 context sentence
    Summary · context
    Seven adult male patients with GH deficiency (GHD) (age, mean+/-S.E.M.: 42.0+/-4.0 year) were studied by equilibrium radionuclide angiocardiography after i.v. administration of hexarelin, a peptide GH secretagogue.
  5. 05HumanNon-randomized trialEfficacy outcome

    In control men, acute hexarelin increased left ventricular ejection fraction over baseline.

    In plain wordsIn healthy men, a single hexarelin dose raised the heart's ejection fraction above baseline.

    Peptide
    Hexarelin
    Outcome
    IncreaseLeft ventricular ejection fraction in controls
    Study

    n = 9

    Comparator
    Baseline
    Outcome group
    Heart function · Cardiovascular
    Studied dose
    Dose not stated · intravenousAs given in this study (human).

    Measurements

    Peak LVEF
    70%
    controls

    Source sentences

    Summary
    Hexarelin administration increased LVEF both in patients with GHD and in CS (peak: 57+/-2 vs. 70+/-2, respectively, P<0.05 vs. baseline) without changing catecholamine levels, mean blood pressure (MBP), or cardiac output in either group.
    1 context sentence
    Summary · context
    Seven adult male patients with GH deficiency (GHD) (age, mean+/-S.E.M.: 42.0+/-4.0 year) were studied by equilibrium radionuclide angiocardiography after i.v. administration of hexarelin, a peptide GH secretagogue.
  6. 06HumanNon-randomized trialEfficacy outcome

    In men with GH deficiency, acute hexarelin increased left ventricular ejection fraction over baseline.

    In plain wordsIn men with growth hormone deficiency, a single hexarelin dose raised the heart's ejection fraction above baseline.

    Peptide
    Hexarelin
    Outcome
    IncreaseLeft ventricular ejection fraction in GH deficiency
    Study

    n = 7

    Comparator
    Baseline
    Outcome group
    Heart function · Cardiovascular
    Studied dose
    Dose not stated · intravenousAs given in this study (human).

    Measurements

    Peak LVEF
    57%
    GH deficiency

    Source sentences

    Summary
    Hexarelin administration increased LVEF both in patients with GHD and in CS (peak: 57+/-2 vs. 70+/-2, respectively, P<0.05 vs. baseline) without changing catecholamine levels, mean blood pressure (MBP), or cardiac output in either group.
    1 context sentence
    Summary · context
    Seven adult male patients with GH deficiency (GHD) (age, mean+/-S.E.M.: 42.0+/-4.0 year) were studied by equilibrium radionuclide angiocardiography after i.v. administration of hexarelin, a peptide GH secretagogue.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    13 Oct 2026, 21:44 UTC

    Study results updated

  2. Version 1

    13 Oct 2026, 16:31 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.